Alzheimer’s disease is the most common form of dementia, affecting more than 55 million people worldwide. Characterized by progressive cognitive decline, memory loss and behavioral changes, it places immense emotional and economic stress on patients, families and healthcare systems. Despite decades of research, effective treatments remain elusive.
One reason for this challenge is the disease’s complex pathology. Alzheimer’s is defined by two major hallmarks in the brain: extracellular amyloid-beta plaques and intracellular neurofibrillary tangles composed of the tau protein.
While amyloid-beta has been a central focus in drug development, increasing evidence points to tau pathology as a more accurate predictor of disease progression.
This is where the work of…